Highlights  RYR1-related myopathies are associated with functional impairments and chronic fatigue  This accounts for congenital myopathies and to a lesser extent for malignant hyperthermia  This results in substantial loss of quality of life
M A N U S C R I P T Introduction
Mutations in RYR1, the gene encoding the sarcoplasmic reticulum (SR) type 1 ryanodine receptor (RyR1), have emerged as the most common genetic cause of non-dystrophic neuromuscular disorders in recent years. [1] RYR1 mutations give rise to a wide variety of myopathies presenting throughout life [2] , ranging from early-onset congenital myopathies (for review, Jungbluth et al. [3] ) to episodic manifestations in adulthood such as exertional rhabdomyolysis (RM), malignant hyperthermia during anesthesia with susceptibility proven by an in vitro contracture test (MH) and periodic paralysis [4] in otherwise healthy individuals. The very wide RYR1-associated clinical spectrum is due to the highly variable functional impact of RYR1 mutations on the RyR1 receptor, the principal skeletal muscle calcium release channel with a crucial role in excitation-contraction coupling (ECC).
The weakness associated with early-onset RYR1-related congenital myopathies may be considerable and pose a substantial disease burden. Although fixed weakness is rare in episodic RYR1-associated RM and MH, individuals presenting with these features may nevertheless experience significant fatigue and myalgia in between episodes. [5] Myalgia may also be a prominent additional feature in early-onset RYR1-related myopathies such as central core disease (CCD), and has been reported in these conditions even before their genetic resolution. [6] Moreover, non-skeletal muscle manifestations, including an increased bleeding tendency and bowel and bladder symptoms due to smooth muscle dysfunction are increasingly recognized, and reflective of RYR1 expression in tissues other than striated skeletal muscle. [2, [7] [8] [9] [10] [11] These complex disease phenotypes are likely to have a substantial impact on the quality of life (QoL) in affected individuals, yet no systematic studies investigating the associated fatigue, pain and functional impairments have been performed in RYR1related disorders to date.
To obtain baseline data concerning the functional impairments, fatigue and QoL associated with these common conditions, we performed a questionnaire study focussing on these features in patients with RYR1-related myopathies throughout the recognized disease spectrum. [2] Standardized A C C E P T E D M A N U S C R I P T 5 questionnaires were used to obtain information on: functional impairments, fatigue, symptoms of psychopathology and other aspects of QoL. We compared patients with RYR1-related myopathies with healthy controls and with patients affected by a progressive neuromuscular disorder with multisystem involvement, MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Strokelike episodes,) spectrum disorder. In addition, within the group of patients with RYR1-related myopathies, the subgroup of patients with 'permanent phenotypes' (congenital myopathies) were compared to the patients with 'episodic phenotypes' (MH and RM).
The results of this explorative study will improve management of patients with RYR1-related myopathies, and enable the definition of areas in need of further research concerning the disease burden associated with these common neuromuscular disorders.
Methods

Patients
All patients with a genetically confirmed RYR1-related disorder seen at the Department of Neurology 
Methods
This study was approved by the regional Ethics Committee: Human Research Committee region Arnhem and Nijmegen (CMO 2016-2954). All participants gave written informed consent.
After informed consent, patients received an email with a link, which led to the questionnaire in a private and secure environment (Radquest 2.0). The patients were asked to open this link and fill in the questionnaires at their preferred place and time. Once commenced, the questionnaire had to be completed within 24 hours to prevent errors in data storage. If the questionnaire was not completed within two weeks, patients received a reminder email. If this neither resulted in completion, a reminder phone call followed after a further two weeks.
Questionnaires
Various aspects of functional impairments, fatigue and QoL were assessed with questionnaires that have been used before and validated in neuromuscular disorders. [12, 13] Functional impairment was assessed using the Sickness Impact Profile (SIP), aimed at assessing changes in everyday activities due to sickness and covering the following dimensions of functioning: sleep/rest (7 items); home management (10 items); mobility (addressing the ability to move indoors and outdoors; 10 items); social interactions (20 items); ambulation (addressing the ability to walk and walk stairs, and use of walking aids; 12 items); alertness behaviour (10 items); work (3 items); and recreation (8 items). [14, 15] Higher scores reflect more impairment. Scores were compared to a group of 83 healthy subjects. [16] Fatigue severity was assessed with the Checklist Individual Strength (CIS). The CIS is a questionnaire with twenty items and the following four subscales: perceived fatigue severity (8 items), concentration (5 items), motivation (4 items) and physical activity (3 items). The total score is calculated by adding up the scores for each subscale (range = 20-140), with higher scores indicative of a higher disease burden. [17] A CIS-fatigue score of 35 or more was used to identify severe fatigue.
A representative sample from the Dutch general population was used as a reference group. [18] A C C E P T E D M A N U S C R I P T 7 Symptoms of psychopathology were assessed by the SLC-90. This questionnaire consists of 90 descriptions of complaints on several subscales (agoraphobia, anxiety, depression, somatisation, obsessive-compulsive behaviour, interpersonal sensitivity, hostility, sleep). The statements are rated on a five-point Likert scale (a psychometric scale commonly involved in questionnaire research with scores 1-5; 1: strongly disagree; 2: disagree; 3: neither agree nor disagree; 4: agree; 5: strongly agree) [19] Higher scores reflect more symptoms of psychopathology. A total SCL-90 score of more than 160 is indicative of high psychological distress, while a score of more than 200 is indicative of a psychiatric disorder. [20, 21] For additional assessment of anxiety and depression the Hospital Anxiety and Depression Scale (HADS), specially developed for the assessment in a hospital population, was used. The HADS includes seven items about depression and seven items about anxiety. Its total score can be used as a measure of general distress. Total scores ≥ 11 are indicative of high distress. [22] [23] The HADS is designed to assess symptoms of depression in people with medical conditions by controlling for vital aspects of depression that could easily interfere with symptoms of the disease.
Overall quality of life was assessed using the RAND-SF36 questionnaire. Subscales investigated several dimensions of QoL (physical functioning, social functioning, emotional functioning, general health status, perceived change in health status, mental health, vitality and pain). Scores range from 0 (maximum limitations) to 100 (optimal functioning). [24] A commonly used representative sample of the Dutch general population (men and women aged 18 to 75 years) was used as a reference group. [25] Statistics. Data analysis was performed using SPSS (version 22). Descriptive statistics were used to describe the characteristics of the sample as well as patient reported outcomes on functional impairment, fatigue, psychological symptoms, and QoL. Fisher exact test was used to compare the response and non-response group (age, sex and phenotype). One-sample t tests were used for the
comparison of RYR1-mutated patients with healthy controls, and a sample of patients with a MELAS spectrum disorder. [13] ANOVA's were used to compare permanent with episodic RYR1-related phenotypes with regards to patient reported outcomes concerning QoL, functional impairment, symptoms of psychopathology , and fatigue. Because of the large number of variables to explore and comparisons to make, and its increased risk of Type 1 errors, Bonferroni adjustments to the alpha level were applied (statistical significance Rand-sf36 p<.006; SIP p<.006; SCL90 p<.006; HADS p<.017; CIS p<.013).
Results
Response
In total 200 invitation letters were sent. Sixty-one patients did not respond after sending two letters and could not be reached by phone on two subsequent attempts. Hence, we managed to contact 139 patients, of which 26 patients responded that they were not willing to participate in this study, and 113 patients agreed to participate. Of these 113 patients, 94 responded with an email address and a consent form (13 of whom did not return their consent form; six did not send an email address; See 
Functional impairment (SIP)
Functional impairment as assessed with the eight dimensions of the Sickness Impact Profile (SIP) is shown in Table 2 . Mean scores on all dimensions reflected more functional impairments in patients with RYR1-related myopathies compared to healthy controls (t values varied from 3.020 (mobility: p=.004) to 6.277 (ambulation: p<.001), except for work (t(71)=2.417, p=.018). Compared to MELAS spectrum disorder patients, RYR1-mutated patients showed less impairment in mobility (t(71)=-3.522, p=.001), social interaction (t(71)=-3.870, p<.001), alertness behavior (t(71)=-6.392, p<.001) and recreation (t(71)=-3.489, p=.001).
Fatigue (CIS)
On the four subscales of the CIS and its total score, RYR1-mutated patients scored significantly higher than healthy controls (t values varied from 3.265 (concentration: p = .002) to 9.201 (fatigue: p<.001), Table 2 . Scores were significantly lower than MELAS spectrum disorder patients. Severe levels of fatigue (CIS fatigue> 35) were reported by 46% of the patients (n=33) compared to 60% in MELAS spectrum disorder patients.
Symptoms of psychopathology (SCL-90)
Scores on the eight subscales of the SCL-90 revealed significant more problems compared to healthy controls on somatisation (t(71)=.038, p<.001. Results are summarized in Table 2 . On the (total score of the) SCL-90, 13% of patients scored above the cut-off for high psychological distress.
Mental functioning (HADS)
In general, patients showed no difference in levels of depression compared to MELAS spectrum disorder patients (t(71)=-.986, p=.327) or healthy Dutch controls (t(71)=2.166, p=.034). Scores on anxiety were better than those of the control group (t(71)=-2.740, p=.008) and the MELAS spectrum disorder patients (t(71)=-3.238, p=.002). General distress was similar to healthy controls (t(71)=.039, p=.969) and better than the MELAS spectrum disorder patients (t(71)=-2.389, p=.020) ( Table 2 ).
Looking at subgroups scoring above the cut-off, results on the HADS indicated that 21% and 17% of the patients experienced clinically relevant symptoms of, respectively, depression and anxiety. One third of the patients (33%) scored above the cut-off of clinical relevant levels of general distress.
Quality of life (RAND36)
Results from the QoL questionnaire study in RYR1-mutated patients are presented in Table 2 . 
Comparison of permanent and episodic phenotypes
Of 72 RYR1-mutated patients, 33 patients had a permanent and 39 had an episodic phenotype. The permanent phenotype group experienced worse physical functioning (F(1,70)=44.6, p<.001), and more functioning impairments in home management (F(1,70)=9.8, p=.003), mobility (F(1,70)=7.3, p=.009), and ambulation (F(1,70)=39.9, p<.001). With regards to psychological functioning and fatigue, no differences between the groups were found.
Regarding QoL, compared to healthy controls patients with a permanent phenotype experienced lower physical (role) and social functioning, less vitality, more pain, worse general health and experienced health change. Regarding functional impairment, they experienced more difficulties in sleep/rest, home management, mobility, social interaction, ambulation, recreation. Furthermore, with regards to psychological functioning, these patients reported more somatisation. With regards to fatigue, patients reported more perceived fatigue, motivation and activity problems (t-values varied from 2.906 (mobility: p=.006) to -10.019 (physical functioning: p<.001). Anxiety levels were significantly lower than those of healthy controls (t=-4.126; p<.001).
Patients with an episodic phenotype reported more perceived fatigue severity and motivation problems, more difficulties in social interaction, and more impairment in recreation and pastimes (t values varied from 3.206 (recreation: p=.003) to 5.447 (fatigue: p<.001) compared to healthy controls. Inspection of single items revealed that these patients report decreased sexual activity, took it slower with some of their usual activities, went out for entertainment less often, enjoyed less recreational activities, and dedicated themselves to hobbies for shorter periods of time.
Discussion
The present questionnaire-based study to our knowledge is the first study to systematically investigate the impact of RYR1-related myopathies in affected individuals, ranging from functional impairments and fatigue to psychological wellbeing and QoL in general. Our study showed that patients with RYR1-related myopathies throughout the recognized disease spectrum have more functional impairments and experienced chronic fatigue compared to healthy controls, with almost half of all patients being severely fatigued (CIS fatigue > 35). Whilst functional impairments and fatigue were more pronounced in those with congenital myopathy phenotypes, individuals with episodic phenotypes also scored higher in all relevant categories compared to healthy controls, but less compared to a multisystem disorder with neuromuscular involvement, MELAS. Although one Findings of increased fatigue as well as impaired physical and social functioning are not unexpected in RYR1-related congenital myopathies (permanent phenotypes), considering the associated variable but often substantial weakness. However, the severity of the associated disease burden suggested by our study is noteworthy, considering that RYR1-related myopathies are often regarded as relatively mild conditions compared to other congenital myopathies. These findings are even more remarkable as our cohort included only adult patients, thus excluding some of the early-onset RYR1-related paediatric manifestations associated with even more profound weakness and disability. Our study also indicates specific areas of malfunctioning in individuals with RYR1-related disorders that might warrant further in-depth exploration, certain aspects of social interaction (such as decreased sexual activity), recreational activities (for example, performing such activities more slowly) and general problems with motivation.
Milder but essentially similar findings in individuals with RYR1-related MH and RM suggest that these conditions are not purely episodic conditions, but do have a phenotype associated with a substantial disease burden also between episodes. The concept of RYR1-related RM exhibiting also interepisodic myopathic features is supported by the additional presence of (exertional) myalgia without demonstrable muscle breakdown in individuals with RYR1-related RM and their carrier relatives, initially reported by our group [5] and independently confirmed in subsequent smaller cohorts from Denmark and South America. [26, 27] One of these series also already suggested an effect on activities of daily living in patients with RYR1-related RM, something which has more systematically been explored in the present study, also with regards to its impact on QoL parameters. Parameters of physical and social functioning as well as QoL in individuals with RYR1-related MH, representing almost all patients with episodic phenotypes in our cohort, are here reported for the first time: these parameters suggest that as in patients with RYR1-related RM, patients with RYR1-related MH do also have a substantial disease burden in daily life, a concept that is currently not well-established.
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Although no systematic studies have been performed yet, earlier observations in isolated families with RYR1-related MH suggest a high prevalence of pain, in particular affecting the lower back muscles [28] , a muscle group that may also become manifestly weak over time in such patients. [29] Taken together, these observations emphasize the previous notion that RYR1-related MH and RM are different but closely related clinical manifestations of the same mutational spectrum, presenting predominantly episodically on triggering but associated with a substantial permanent disease burden in daily life.
Although no detailed QoL studies have been reported in RYR1-related and other congenital myopathies to date, similar studies have been performed in other, mainly dystrophic neuromuscular disorders such as Duchenne muscular dystrophy, myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), but also neurogenic conditions such as spinal muscular atrophy. [30] [31] [32] [33] These studies may serve as a point of comparison for the present study but may also help to delineate specific determinants of impaired QoL in neuromuscular disorders. In particular, comparison with previously reported cohorts of FSHD (n=139), DM1 (n=322), and hereditary motor and sensory neuropathy type I (HMSN; n=137) from our centre showed a lower prevalence of severe fatigue (CIS fatigue≥35) in patients with RYR1-related myopathies (46% vs 61%, 74% and 64% respectively; p=0.04; p,0.0001; p=0.01 respectively). [34] In this previous study, regression analyses were carried out to determine the contribution of different dimensions to fatigue severity. [34] The number of patients in our current study was too small to perform a similar analysis, however, this ought to be considered in larger prospective studies in future concerning RYR1-related and other congenital myopathies. Impairment of physical activity and muscle strength, important contributors to altered QoL in conditions such as FSHD and DM1 [35] , are likely to have contributed to impaired QoL in RYR1related congenital myopathies (permanent phenotypes) but are unlikely to explain similar observations in RYR1-related RM and MH, considering that individuals with these episodic phenotypes are normally strong (or even particularly athletic). It is conceivable that the absence of M A N U S C R I P T 14 weakness in combination with a large muscle mass in some of these individuals may enable them to participate effectively in strenuous sports (personal observation), an ability that in turn might predispose to a higher incidence of ERM, muscle fatigue and an adverse effect on QoL. The common occurrence of high levels of physical fitness and reduced exercise tolerance or lower fatigue thresholds in some individuals with RYR1-related episodic phenotypes may reflect specific effects of the dominant RYR1 gain-of-function mutations typically underlying such phenotypes. Although not the focus of the present study, such mechanisms warrant further investigation in future, and may include (i) fatigue caused by continuous stimulation of SERCA activity indirectly mediated through a "leaky" RyR1 channel; (ii) high circulating levels of IL-6 in RYR1 mutation carriers causing chronic pain both at rest and during activity [36, 37] ; and (iii) fear of (recurrence of) rhabdomyolysis limiting the motivation to exercise in some patients. From a practical point of view, it is noteworthy that the substantial disease burden caused by exertional myalgia and fatigue may not be immediately obvious in patients with RYR1-related MH, considering their lack of weakness and often athletic muscle build; this is something that ought to be considered. [38, 39] Therefore, counseling of these patients should extend beyond prevention of recurrent MH or RM episodes, and include rehabilitation focused on pain and fatigue.
Considering that RYR1-related myopathies may show some multisystem features, we also compared RYR1-mutated patients with patients affected by MELAS, a mitochondrial multisystem disorder with muscle and brain features. In comparison to MELAS, RYR1-mutated patients generally have a better QoL, less functional impairment, less anxiety, less perceived fatigue, and are less often severely fatigued. This is not unexpected, considering that MELAS is a more extensive condition. A better example for comparison appears McArdle disease, another neuromuscular disorder with an often severe episodic phenotype that however has substantial permanent features, as evidenced by a recent questionnaire study including 81 patients, demonstrating lower clinical scores compared to the general population in physical domains of health-related QoL parameters. [40] A C C E P T E D M A N U S C R I P T 15 The main limitation of this study relates to the low response rate of 52% of patients who were invited to participate (or 77% of patients who had initially agreed to participate after having been invited), suggesting a potential selection bias. Although there were no differences in age and sex between the response and non-response group, the non-response group consisted of more patients with the episodic phenotype than the response group, suggesting that our results may be more reflective of the latter. In addition and non-regarding specific subgroups, more symptomatic patients may be more inclined to participate in such a symptom-centred questionnaire study, thus potentially leading to an overestimation of the severity of the associated disease phenotype. As a result of the cross-sectional questionnaire study design, we could not identify the causes of functional impairments and loss of QoL. Based on the limitations as outlined, more extensive prospective longitudinal studies focussing on RYR1-related myopathies will be required.
In conclusion, the present study demonstrates that both permanent and episodic RYR1-related disorders are associated with a substantial disease burden, characterized by functional limitations and severe fatigue, and a resulting loss of QoL. As such, our study challenges the concept of RYR1- 
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